This is the authors' abstract. We don't add key points for this paper.
MOTIVATION: Drug repurposing is a potential alternative to the classical drug discovery pipeline. Repurposing involves finding novel indications for already approved drugs. In this work, we present a novel machine learning-based method for drug repurposing. This method explores the anti-similarity between drugs and a disease to uncover new uses for the drugs. More specifically, our proposed method takes into account three sources of information: (i) large-scale gene expression profiles corresponding to human cell lines treated with small molecules, (ii) gene expression profile of a human disease and (iii) the known relationship between Food and Drug Administration (FDA)-approved drugs and diseases. Using these data, our proposed method learns a similarity metric through a supervised machine learning-based algorithm such that a disease and its associated FDA-approved drugs have smaller distance than the other disease-drug pairs. RESULTS: We validated our framework by showing that the proposed method incorporating distance metric learning technique can retrieve FDA-approved drugs for their approved indications. Once validated, we used our approach to identify a few strong candidates for repurposing. AVAILABILITY AND IMPLEMENTATION: The R scripts are available on demand from the authors. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Saberian et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: